Literature DB >> 15066232

Complications of androgen deprivation therapy in men with prostate cancer.

Allen C Chen1, Daniel P Petrylak.   

Abstract

Androgen deprivation therapy (ADT) is indicated for the treatment of metastatic prostate cancer and locally advanced disease. In addition to sexual side effects, long-term ADT results in several other changes, including hot flashes; gynecomastia; changes in body composition, metabolism, and the cardiovascular system; osteoporosis; anemia; psychiatric and cognitive problems; and fatigue and diminished quality of life. This review discusses these complications of ADT and treatments aimed at reducing them. It is important for clinicians to anticipate these effects and to initiate measures to prevent or minimize them in order to maintain quality of life in prostate cancer survivors.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15066232     DOI： 10.1007/s11912-004-0051-0

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  59 in total

1.  Fatigue in patients with prostate cancer receiving hormone therapy.

Authors:  P Stone; J Hardy; R Huddart; R A'Hern; M Richards
Journal:  Eur J Cancer       Date:  2000-06       Impact factor: 9.162

2.  Regionally selective effects of gonadectomy on cortical catecholamine innervation in adult male rats are most disruptive to afferents in prefrontal cortex.

Authors:  M F Kritzer; A Adler; J Marotta; T Smirlis
Journal:  Cereb Cortex       Date:  1999 Jul-Aug       Impact factor: 5.357

3.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

Authors:  J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

4.  Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens.

Authors:  J F Caubet; T D Tosteson; E W Dong; E M Naylon; G W Whiting; M S Ernstoff; S D Ross
Journal:  Urology       Date:  1997-01       Impact factor: 2.649

5.  Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons.

Authors:  J Hammond; Q Le; C Goodyer; M Gelfand; M Trifiro; A LeBlanc
Journal:  J Neurochem       Date:  2001-06       Impact factor: 5.372

6.  Progressive osteoporosis during androgen deprivation therapy for prostate cancer.

Authors:  H W Daniell; S R Dunn; D W Ferguson; G Lomas; Z Niazi; P T Stratte
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

7.  Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: a pilot study.

Authors:  M Hammar; J Frisk; O Grimås; M Höök; A C Spetz; Y Wyon
Journal:  J Urol       Date:  1999-03       Impact factor: 7.450

8.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

9.  Transdermal clonidine for ameliorating post-orchiectomy hot flashes.

Authors:  C L Loprinzi; R M Goldberg; J R O'Fallon; S K Quella; A W Miser; L A Mynderse; L D Brown; L K Tschetter; M B Wilwerding; M Dose
Journal:  J Urol       Date:  1994-03       Impact factor: 7.450

10.  Androgen deprivation and cognition in prostate cancer.

Authors:  E Salminen; R Portin; J Korpela; H Backman; L-M Parvinen; H Helenius; M Nurmi
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640
View more
  9 in total

1.  Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.

Authors:  Morgan Lee; Heather S Jim; Mayer Fishman; Babu Zachariah; Randy Heysek; Matthew Biagioli; Paul B Jacobsen
Journal:  Psychooncology       Date:  2014-06-13       Impact factor: 3.894

2.  Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis.

Authors:  Giandomenico Roviello; Daniele Generali
Journal:  Med Oncol       Date:  2018-01-31       Impact factor: 3.064

3.  Estrogenic side effects of androgen deprivation therapy.

Authors:  Theresa A Guise; Michael G Oefelein; James A Eastham; Michael S Cookson; Celestia S Higano; Matthew Raymond Smith
Journal:  Rev Urol       Date:  2007

4.  Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer.

Authors:  Lior Z Braunstein; Ming-Hui Chen; Marian Loffredo; Philip W Kantoff; Anthony V D'Amico
Journal:  Prostate Cancer       Date:  2014-04-22

5.  Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer.

Authors:  C J D Wallis; P Cheung; S Herschorn; R Saskin; J Su; L H Klotz; G S Kulkarni; Y Lee; R T Kodama; S A Narod; R K Nam
Journal:  Br J Cancer       Date:  2015-03-17       Impact factor: 7.640

6.  International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries.

Authors:  Alexander Liede; David C Hallett; Kirsty Hope; Alex Graham; Jorge Arellano; Vahakn B Shahinian
Journal:  ESMO Open       Date:  2016-03-18

7.  Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder.

Authors:  Shiu-Dong Chung; Li-Ting Kao; Herng-Ching Lin; Sudha Xirasagar; Chung-Chien Huang; Hsin-Chien Lee
Journal:  PLoS One       Date:  2017-03-02       Impact factor: 3.240

8.  Severe gynecomastia due to anti androgens intake: A case report and literature review.

Authors:  Farida Chentli; Chentli Farida; Faiza Belhimer; Belhimer Faiza
Journal:  Indian J Endocrinol Metab       Date:  2013-07

Review 9.  Potential role for metformin in urologic oncology.

Authors:  Rashid Khalid Sayyid; Neil Eric Fleshner
Journal:  Investig Clin Urol       Date:  2016-05-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.